Myelodysplastic Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for myelodysplastic syndrome. 18 active patents protecting 2 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

2
Approved drugs
18
Active US patents
64/100
Avg vulnerability
$5.8B
Annual revenue covered

Originators in Myelodysplastic Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 18 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating myelodysplastic syndrome. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
27
6
28
4
29
2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Revlimid
lenalidomide
 Bristol-Myers Squibb 12 54 $5.8B 2027-04-27
Vidaza
azacitidine
 Bristol-Myers Squibb 6 73 — 2029-05-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12053482 Vidaza method of use 88 2029-05-14
12053482 Vidaza method of use 88 2029-05-14
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8846628 Vidaza method of use 68 2030-06-03
8846628 Vidaza method of use 68 2030-06-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
11571436 Vidaza formulation 63 2029-05-14
11571436 Vidaza formulation 63 2029-05-14
8846628 Vidaza method of use 68 2030-06-03
8846628 Vidaza method of use 68 2030-06-03

Related